Moberg Pharma: European application submitted as planned - Redeye

Redeye views the submittal of the full application of the marketing authorization for MOB-015 as positive, although expected. This application aligns with what the company has indicated earlier with a possible first market approval and launch in 2023.

Länk till analysen i sin helhet: https://www.redeye.se/research/837204/moberg-pharma-european-application-submitted-as-planned?utm_source=finwire&utm_medium=RSS